Keywords
Last Name
Institution

Matthew Galsky

TitleASSOCIATE PROFESSOR
InstitutionMount Sinai
DepartmentHematology and Medical Oncology
Address1470 Madison Avenue
3rd floor
New York NY 10029
Phone212-241-6756
    Other Positions
    TitleASSISTANT PROFESSOR
    InstitutionMount Sinai
    DepartmentUrology


     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Pond G, Godbold J, Oh WK, Bamias A. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. Urol Oncol. 2014 Jan; 32(1):48.e1-8.
      View in: PubMed
    2. Funakoshi T, Latif A, Galsky MD. Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2013 Oct; 88(1):30-41.
      View in: PubMed
    3. Linton A, Pond G, Clarke S, Vardy J, Galsky M, Sonpavde G. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin Genitourin Cancer. 2013 Dec; 11(4):423-30.
      View in: PubMed
    4. Pond GR, Bellmunt J, Fougeray R, Choueiri TK, Qu AQ, Niegisch G, Albers P, Di Lorenzo G, Salhi Y, Galsky MD, Agarwal N, Necchi A, Sonpavde G. Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design. Clin Genitourin Cancer. 2013 Dec; 11(4):495-500.
      View in: PubMed
    5. Kaymakcalan MD, Je Y, Sonpavde G, Galsky M, Nguyen PL, Heng DY, Richards CJ, Choueiri TK. Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors. Br J Cancer. 2013 Jun 25; 108(12):2478-84.
      View in: PubMed
    6. Galsky MD, Oh WK. Tumour angiogenesis: an elusive target in castration-resistant prostate cancer. Lancet Oncol. 2013 Jul; 14(8):681-2.
      View in: PubMed
    7. Galsky MD, Krege S, Lin CC, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy. Cancer. 2013 Aug 15; 119(16):3020-6.
      View in: PubMed
    8. Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh WK, Bamias A. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer. 2013 Aug 15; 119(16):3012-9.
      View in: PubMed
    9. Galsky MD, Xie W, Nakabayashi M, Ross RW, Fennessy FM, Tempany CM, Choueiri TK, Khine K, Kantoff PW, Taplin ME, Oh WK. Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer. Prostate Cancer Prostatic Dis. 2013 Sep; 16(3):266-70.
      View in: PubMed
    10. Sonpavde G, Galsky MD, Bellmunt J. A new approach to second-line therapy for urothelial cancer? Lancet Oncol. 2013 Jul; 14(8):682-4.
      View in: PubMed
    11. Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev. 2014 Feb; 40(1):190-6.
      View in: PubMed
    12. Goyal J, Pond GR, Galsky MD, Hendricks R, Small A, Tsao CK, Sonpavde G. Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer. Urol Oncol. 2014 Jan; 32(1):36.e27-34.
      View in: PubMed
    13. Haines L, Bamias A, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Galsky MD. The impact of gender on outcomes in patients with metastatic urothelial carcinoma. Clin Genitourin Cancer. 2013 Sep; 11(3):346-52.
      View in: PubMed
    14. Choueiri TK, Je Y, Sonpavde G, Richards CJ, Galsky MD, Nguyen PL, Schutz F, Heng DY, Kaymakcalan MD. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. Ann Oncol. 2013 Aug; 24(8):2092-7.
      View in: PubMed
    15. Funakoshi T, Latif A, Galsky MD. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis. J Hum Hypertens. 2013 Oct; 27(10):601-11.
      View in: PubMed
    16. Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O, Tammela TL, Calais da Silva F. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol. 2013 Nov; 64(5):722-30.
      View in: PubMed
    17. Tsao CK, Liaw B, Yee T, Galsky MD, Oh WK. Metabolic and toxicological considerations of newly approved prostate cancer drugs. Expert Opin Drug Metab Toxicol. 2013 Jul; 9(7):835-46.
      View in: PubMed
    18. Galsky MD, Hendricks R, Svatek R, Bangs R, Hoffman-Censits J, Clement J, Dreicer R, Guancial E, Hahn N, Lerner SP, O'Donnell PH, Quale DZ, Siefker-Radtke A, Shipley W, Sonpavde G, Vaena D, Vinson J, Rosenberg J. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer. 2013 Jun 1; 119(11):1994-8.
      View in: PubMed
    19. Funakoshi T, Latif A, Galsky MD. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis. Cancer Treat Rev. 2013 Nov; 39(7):818-30.
      View in: PubMed
    20. Galsky MD, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. Urol Oncol. 2014 Jan; 32(1):30.e15-21.
      View in: PubMed
    21. Galsky MD, Domingo-Domenech J. Advances in the management of muscle-invasive bladder cancer through risk prediction, risk communication, and novel treatment approaches. Clin Adv Hematol Oncol. 2013 Feb; 11(2):86-92.
      View in: PubMed
    22. Maughan BL, Agarwal N, Hussain SA, Boucher KM, Von Der Maase H, Kaufman DS, Lorusso V, Moore MJ, Galsky MD, Sonpavde G. Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer. 2013 Sep; 11(3):316-20.
      View in: PubMed
    23. Sonpavde G, Je Y, Schutz F, Galsky MD, Paluri R, Rosenberg JE, Bellmunt J, Choueiri TK. Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2013 Jul; 87(1):80-9.
      View in: PubMed
    24. Galsky MD. A prognostic model for metastatic renal-cell carcinoma. Lancet Oncol. 2013 Feb; 14(2):102-3.
      View in: PubMed
    25. Galsky MD, Hahn NM, Powles T, Hellerstedt BA, Lerner SP, Gardner TA, Yu M, O'Rourke M, Vogelzang NJ, Kocs D, McKenney SA, Melnyk AM, Hutson TE, Rauch M, Wang Y, Asmar L, Sonpavde G. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer. 2013 Jun; 11(2):175-81.
      View in: PubMed
    26. Tsao CK, Small AC, Kates M, Moshier EL, Wisnivesky JP, Gartrell BA, Sonpavde G, Godbold JH, Palese MA, Hall SJ, Oh WK, Galsky MD. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World J Urol. 2013 Dec; 31(6):1535-9.
      View in: PubMed
    27. Tsao CK, Gartrell BA, Oh WK, Galsky MD. Emerging personalized approaches for the management of advanced urothelial carcinoma. Expert Rev Anticancer Ther. 2012 Dec; 12(12):1537-43.
      View in: PubMed
    28. Sonpavde G, Pond GR, Fougeray R, Choueiri TK, Qu AQ, Vaughn DJ, Niegisch G, Albers P, James ND, Wong YN, Ko YJ, Sridhar SS, Galsky MD, Petrylak DP, Vaishampayan UN, Khan A, Vogelzang NJ, Beer TM, Stadler WM, O'Donnell PH, Sternberg CN, Rosenberg JE, Bellmunt J. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol. 2013 Apr; 63(4):717-23.
      View in: PubMed
    29. Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol. 2012 Dec 10; 30(35):4416-26.
      View in: PubMed
    30. Proverbs-Singh T, Chiu SK, Liu Z, Seng S, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. J Natl Cancer Inst. 2012 Dec 5; 104(23):1837-40.
      View in: PubMed
    31. Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, Katz L, Subudhi SK, Anand A, Fleisher M, Kantoff PW, Oh WK. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol. 2012 Nov; 13(11):1105-13.
      View in: PubMed
    32. Pond GR, Berry WR, Galsky MD, Wood BA, Leopold L, Sonpavde G. Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2012 Dec; 10(4):239-45.
      View in: PubMed
    33. Tsao CK, Galsky MD, Small AC, Yee T, Oh WK. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU Int. 2012 Dec; 110(11):1580-8.
      View in: PubMed
    34. Galsky MD. Editorial comment. J Urol. 2012 Oct; 188(4):1114.
      View in: PubMed
    35. Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013 Jan; 63(1):58-66.
      View in: PubMed
    36. Galsky MD. Antiangiogenic treatment in metastatic urothelial cancer. Lancet Oncol. 2012 Aug; 13(8):748-9.
      View in: PubMed
    37. Tong CC, Ko EC, Sung MW, Cesaretti JA, Stock RG, Packer SH, Forsythe K, Genden EM, Schwartz M, Lau KH, Galsky M, Ozao-Choy J, Chen SH, Kao J. Phase II trial of concurrent sunitinib and image-guided radiotherapy for oligometastases. PLoS One. 2012; 7(6):e36979.
      View in: PubMed
    38. Small AC, Tsao CK, Moshier EL, Gartrell BA, Wisnivesky JP, Godbold JH, Smith CB, Sonpavde G, Oh WK, Galsky MD. Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. Cancer. 2012 Dec 1; 118(23):5947-54.
      View in: PubMed
    39. Galsky MD, Tagawa ST, Shariat SF. Is adjunctive systemic chemotherapy after cystectomy for T2N+ disease of therapeutic benefit? J Urol. 2012 Aug; 188(2):358-60.
      View in: PubMed
    40. Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, Katz S, Albano T, Arnovitz P, Okrent R, Ohlmeyer M, Galsky M, Burstein D, Zhang D, Politi K, Difeo A, Narla G. Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. J Clin Invest. 2012 Jul 2; 122(7):2637-51.
      View in: PubMed
    41. Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T, Sternberg CN, Sonpavde G. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012 Sep; 62(3):523-33.
      View in: PubMed
    42. Sivendran S, Liu Z, Portas LJ, Yu M, Hahn N, Sonpavde G, Oh WK, Galsky MD. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. Cancer Treat Rev. 2012 Nov; 38(7):919-25.
      View in: PubMed
    43. Tsao CK, Small AC, Moshier EL, Gartrell BA, Wisnivesky JP, Sonpavde G, Godbold JH, Palese MA, Hall SJ, Oh WK, Galsky MD. Trends in the use of cytoreductive nephrectomy in the United States. Clin Genitourin Cancer. 2012 Sep; 10(3):159-63.
      View in: PubMed
    44. Small AC, Tsao CK, Moshier EL, Gartrell BA, Wisnivesky JP, Godbold J, Sonpavde G, Palese MA, Hall SJ, Oh WK, Galsky MD. Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States. World J Urol. 2013 Oct; 31(5):1211-7.
      View in: PubMed
    45. Small AC, Gong Y, Oh WK, Hall SJ, van Rijn CJ, Galsky MD. The emerging role of circulating tumor cell detection in genitourinary cancer. J Urol. 2012 Jul; 188(1):21-6.
      View in: PubMed
    46. Pond GR, Armstrong AJ, Galsky MD, Wood BA, Leopold L, Sonpavde G. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials. Urol Oncol. 2013 Nov; 31(8):1457-63.
      View in: PubMed
    47. Tsao CK, Small AC, Galsky MD, Oh WK. Overcoming castration resistance in prostate cancer. Curr Opin Urol. 2012 May; 22(3):167-74.
      View in: PubMed
    48. Galsky MD, Small AC, Tsao CK, Oh WK. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes. CA Cancer J Clin. 2012 Sep-Oct; 62(5):299-308.
      View in: PubMed
    49. Pond GR, Armstrong AJ, Wood BA, Leopold L, Galsky MD, Sonpavde G. Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. BJU Int. 2012 Dec; 110(11 Pt B):E461-8.
      View in: PubMed
    50. Gartrell BA, Tsao CK, Galsky MD. The follicle-stimulating hormone receptor: A novel target in genitourinary malignancies. Urol Oncol. 2013 Nov; 31(8):1403-7.
      View in: PubMed
    51. Sonpavde G, Vogelzang NJ, Galsky MD, Raghavan VA, Daniel S. Objective measures of physical functional capacity warrant exploration to complement or replace the subjective physician estimated performance status. Am J Clin Oncol. 2012 Apr; 35(2):163-6.
      View in: PubMed
    52. Galsky MD. Editorial comment. J Urol. 2012 May; 187(5):1554.
      View in: PubMed
    53. Fleming MT, Sonpavde G, Kolodziej M, Awasthi S, Hutson TE, Martincic D, Rastogi A, Rousey SR, Weinstein RE, Galsky MD, Berry WR, Wang Y, Boehm KA, Asmar L, Rauch MA, Beer TM. Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2012 Mar; 10(1):6-14.
      View in: PubMed
    54. Svatek RS, Rosenberg JE, Galsky MD, Lee CT, Latini DM, Bochner BH, Weizer AZ, Apolo AB, Sridhar SS, Kamat AM, Hansel D, Flaig TW, Smith ND, Lotan Y. Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research. Urol Oncol. 2013 Oct; 31(7):968-73.
      View in: PubMed
    55. Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer. 2012 Oct 1; 118(19):4777-84.
      View in: PubMed
    56. Tsao CK, Moshier E, Seng SM, Godbold J, Grossman S, Winston J, Oh WK, Galsky MD. Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer. Clin Genitourin Cancer. 2012 Mar; 10(1):15-20.
      View in: PubMed
    57. Sonpavde G, Matveev V, Burke JM, Caton JR, Fleming MT, Hutson TE, Galsky MD, Berry WR, Karlov P, Holmlund JT, Wood BA, Brookes M, Leopold L. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann Oncol. 2012 Jul; 23(7):1803-8.
      View in: PubMed
    58. Galsky MD, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors. Ann Oncol. 2012 Apr; 23(4):1037-44.
      View in: PubMed
    59. Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross RW. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology. 2011 Sep; 78(3):626-30.
      View in: PubMed
    60. Patel JD, Galsky MD, Chagpar AB, Pyle D, Loehrer PJ. Role of American Society of Clinical Oncology in low- and middle-income countries. J Clin Oncol. 2011 Aug 1; 29(22):3097-102.
      View in: PubMed
    61. Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy. Clin Genitourin Cancer. 2011 Sep; 9(1):27-30.
      View in: PubMed
    62. Tsao CK, Seng S, Oh WK, Galsky MD. Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. Clin Med Insights Oncol. 2011; 5:163-9.
      View in: PubMed
    63. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol. 2011 Jun 10; 29(17):2432-8.
      View in: PubMed
    64. Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012 Feb; 23(2):406-10.
      View in: PubMed
    65. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011 Mar; 12(3):211-4.
      View in: PubMed
    66. Jotte R, Conkling P, Reynolds C, Galsky MD, Klein L, Fitzgibbons JF, McNally R, Renschler MF, Oliver JW. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol. 2011 Jan 20; 29(3):287-93.
      View in: PubMed
    67. Galsky MD, Hall SJ. Bladder cancer: current management and opportunities for a personalized approach. Mt Sinai J Med. 2010 Nov-Dec; 77(6):587-96.
      View in: PubMed
    68. Galsky MD, Von Hoff DD, Neubauer M, Anderson T, Fleming M, Nagarwala Y, Mahoney JM, Midwinter D, Vocila L, Zaks TZ. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs. 2012 Apr; 30(2):695-701.
      View in: PubMed
    69. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. Cabazitaxel. Nat Rev Drug Discov. 2010 Sep; 9(9):677-8.
      View in: PubMed
    70. Sonpavde G, Galsky MD, Vogelzang NJ. First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients? J Clin Oncol. 2010 Sep 1; 28(25):e441-2; author reply e443-4.
      View in: PubMed
    71. Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol. 2010 Sep; 11(9):861-70.
      View in: PubMed
    72. Galsky MD. Bladder cancer: advances in treatment and research. Clin Adv Hematol Oncol. 2010 Apr; 8(4):234-6.
      View in: PubMed
    73. Galsky MD, Vogelzang NJ. Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol. 2010 Nov; 21(11):2135-44.
      View in: PubMed
    74. Sonpavde G, Rosenberg JE, Hahn NM, Galsky MD, Bangs R, Sternberg CN, Vogelzang NJ. Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma. J Clin Oncol. 2010 May 1; 28(13):e205-7; author reply e208.
      View in: PubMed
    75. Sonpavde G, Aparicio AM, Zhan F, North B, Delaune R, Garbo LE, Rousey SR, Weinstein RE, Xiao L, Boehm KA, Asmar L, Fleming MT, Galsky MD, Berry WR, Von Hoff DD. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer. Urol Oncol. 2011 Nov-Dec; 29(6):682-9.
      View in: PubMed
    76. Sonpavde G, Periman PO, Bernold D, Weckstein D, Fleming MT, Galsky MD, Berry WR, Zhan F, Boehm KA, Asmar L, Hutson TE. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol. 2010 Feb; 21(2):319-24.
      View in: PubMed
    77. Galsky MD, Simon K, Sonpavde G, Hutson TE, Fleming M, Kondagunta GV, Berry W. Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer. Ann Oncol. 2009 May; 20(5):965-6.
      View in: PubMed
    78. Young LR, Franz DN, Nagarkatte P, Fletcher CD, Wikenheiser-Brokamp KA, Galsky MD, Corbridge TC, Lam AP, Gelfand MJ, McCormack FX. Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis. Chest. 2009 Sep; 136(3):926-33.
      View in: PubMed
    79. Sonpavde G, Galsky MD, Hutson TE, Von Hoff DD. Patient selection for phase II trials. Am J Clin Oncol. 2009 Apr; 32(2):216-9.
      View in: PubMed
    80. Galsky MD, Zaks T, Hassani H, Vocila L, Sonpavde G, Hutson TE, Von Hoff DD. Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. Invest New Drugs. 2010 Apr; 28(2):194-8.
      View in: PubMed
    81. Sonpavde G, Fleming MT, Hutson TE, Galsky MD. Trial design for metastatic castration-resistant prostate cancer. J Clin Oncol. 2008 Jul 20; 26(21):3647-8; author reply 3648-9.
      View in: PubMed
    82. Galsky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin SF, DeLaCruz A, Lee Y, Webb IJ, Scher HI. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol. 2008 May 1; 26(13):2147-54.
      View in: PubMed
    83. Sonpavde G, Galsky MD, Hutson TE. Current optimal chemotherapy for advanced urothelial cancer. Expert Rev Anticancer Ther. 2008 Jan; 8(1):51-61.
      View in: PubMed
    84. Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Berry WR, Kadmon D. Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer. 2007 Dec 15; 110(12):2628-39.
      View in: PubMed
    85. Sonpavde G, Ross R, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Lerner SP, Sternberg CN. Novel agents for muscle-invasive and advanced urothelial cancer. BJU Int. 2008 Apr; 101(8):937-43.
      View in: PubMed
    86. Kondagunta V, Galsky MD, Sonpavde G. Germ-cell tumors. N Engl J Med. 2007 Oct 25; 357(17):1773; author reply 1773-4.
      View in: PubMed
    87. Galsky MD, Vogelzang NJ. Outcomes and prognosis in advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2007 Jun; 7(6):839-45.
      View in: PubMed
    88. Galsky MD, Kelly WK. High-dose bicalutamide after radiotherapy for locally advanced prostate cancer: a standard of care? Nat Clin Pract Urol. 2007 Mar; 4(3):134-5.
      View in: PubMed
    89. Galsky MD, Iasonos A, Mironov S, Scattergood J, Donat SM, Bochner BH, Herr HW, Russo P, Boyle MG, Bajorin DF. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology. 2007 Feb; 69(2):255-9.
      View in: PubMed
    90. Galsky MD, Iasonos A, Mironov S, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer. 2007 Feb 1; 109(3):549-55.
      View in: PubMed
    91. Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs. 2007 Jun; 25(3):265-70.
      View in: PubMed
    92. Hutson TE, Sonpavde G, Galsky MD. Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials. Clin Genitourin Cancer. 2006 Dec; 5 Suppl 1:S31-9.
      View in: PubMed
    93. Sonpavde G, Hutson TE, Galsky MD, Berry WR. Problems with the randomized discontinuation design. J Clin Oncol. 2006 Oct 1; 24(28):4669-70; author reply 4670-1.
      View in: PubMed
    94. Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, Bochner BH. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006 Aug 1; 107(3):506-13.
      View in: PubMed
    95. Slovin SF, Galsky MD, Busam K. Violaceous exanthem as a manifestation of metastatic prostate cancer in skin. Urology. 2006 Feb; 67(2):420.
      View in: PubMed
    96. Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer. 2006 Jan 1; 106(1):58-62.
      View in: PubMed
    97. Galsky MD. The role of taxanes in the management of bladder cancer. Oncologist. 2005 Nov-Dec; 10(10):792-8.
      View in: PubMed
    98. Ross RW, Manola J, Hennessy K, Galsky M, Scher H, Small E, Kelly WK, Kantoff PW. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy. Clin Cancer Res. 2005 Jul 15; 11(14):5195-8.
      View in: PubMed
    99. Galsky MD, Scher HI. Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)? J Clin Oncol. 2005 Aug 1; 23(22):4823-6.
      View in: PubMed
    100. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005 Mar 1; 23(7):1439-46.
      View in: PubMed
    101. Galsky MD, Herr HW, Bajorin DE. The integration of chemotherapy and surgery for bladder cancer. J Natl Compr Canc Netw. 2005 Jan; 3(1):45-51.
      View in: PubMed
    102. Galsky M, Kelly WK. Use of nomograms for predicting survival in patients with castrate prostate cancer. Urology. 2003 Dec 29; 62 Suppl 1:119-27.
      View in: PubMed
    103. Smaletz O, Galsky M, Scher HI, DeLaCruz A, Slovin SF, Morris MJ, Solit DB, Davar U, Schwartz L, Kelly WK. Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol. 2003 Oct; 14(10):1518-24.
      View in: PubMed
    104. Galsky M, Kelly WK. The development of differentiation agents for the treatment of prostate cancer. Semin Oncol. 2003 Oct; 30(5):689-97.
      View in: PubMed
    105. Slepecky NB, Galsky MD, Swartzentruber-Martin H, Savage J. Study of afferent nerve terminals and fibers in the gerbil cochlea: distribution by size. Hear Res. 2000 Jun; 144(1-2):124-34.
      View in: PubMed
    106. Galsky M, Darling M, Hecht J, Salgia R. Case 1: small bowel obstruction due to metastatic lung cancer. J Clin Oncol. 2000 Jan; 18(1):227-8.
      View in: PubMed
    Galsky's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067